Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Crucell  /  Draadje OT, bijzaken & geleuter in de marge!

Ontvang nu dagelijks onze kooptips!

word abonnee

Crucell« Terug naar discussie overzicht

Draadje OT, bijzaken & geleuter in de marge!

1.189 Posts
Pagina: «« 1 ... 5 6 7 8 9 ... 60 »» | Laatste | Omlaag ↓
  1. [verwijderd] 6 april 2006 10:38
    VaxGen says surprised by call for vaccine probe Wed Apr 5, 11:54 PM ET

    NEW YORK (Reuters) - VagGen Inc. on Wednesday said it was surprised by a call for an investigation into its U.S. government anthrax vaccine contract made by a U.S. congressman, but said it would cooperate with the probe if there is one.

    VaxGen said it believed the $877 million contract for 75 million doses of its vaccine was won following an open, competitive and fair bidding process that, "to the best of our knowledge, complied with any and all applicable laws, rules and regulations."

    VaxGen Chief Executive Lance Gordon said he was surprised to see media reports of an investigation being proposed by Congressman Mike Rogers of Michigan.

    "We have reached out to Congressman Rogers this evening in an effort to address his concerns, but have yet to hear from him," Gordon said in a statement.

    "Although we believe there are no grounds for an investigation, if there is one, we look forward to fully and openly participating in it. We also welcome the opportunity to testify before any appropriate committee of Congress to explain the contract and our progress in developing a modern anthrax vaccine," Gordon added.

    The Brisbane, California-based company last month said it was at least a year behind schedule in delivering the vaccine after it failed a key human trial.

    And on Tuesday the U.S. Food and Drug Administration released a warning letter it sent to VaxGen, admonishing the company for exaggerating the benefits of its experimental anthrax vaccine at a meeting last October.

    The agency said the biotech company overstated the strength and purity of the vaccine, and said it had made misleading statements about its superiority over a rival company's anthrax vaccine.

    vaccines.org/vacnews.htm
    ***********************
    www.iex.nl/forum/topic.asp?forum=228&...
  2. [verwijderd] 6 april 2006 16:56
    04/06/2006
    Genentech fetes 30-year history
    By David Morrill, BUSINESS WRITER

    IT WAS 30 years ago Friday that a venture capitalist and a biochemist sat down with a radical thought.
    Could a pioneer technology creating artificial DNA flourish in a company whose goal would be generating money-making products?

    The answer was yes. The thought blossomed into South San Francisco-based Genentech Inc., which three decades later has a market cap of $86 billion, 12 marketed products and a goal of being the number one U.S. cancer company in sales by 2010.

    "The experiment that many of us set out in pursuit of was if we could capitalize on the basics of science in the context of a business company," said Arthur Levinson, chief executive of Genentech, who has been with the company for 25 years.

    Genentech was founded on April 7, 1976, by Robert Swanson and Herbert Boyer. The company's goal was to take advantage of a new technology of being able to take DNA from multiple sources and combine it into a single molecule. The technology is known as recombinant DNA.

    On Wednesday, in honor of the anniversary, the company announced a donation of $2.5 million to Cold Spring Harbor Laboratory in New York to build expanded facilities at this well-known think tank for scientists.

    On hand was 1962 Nobel Prize winner James Watson, who with the late Francis Crick, discovered the double helical structure for DNA.

    Watson believes that because of advances and tools developed largely through the Human Genome Projectthat cancer could be "under control" in the next 25 years.

    "All I can say is thank God biotech came along," Watson said. "The only thing I wish was that I personally invested in Genentech stock back then."

    Some of Genentech's blockbuster cancer drugs, such as Herceptin and Avastin, were developed using recombinant DNA technology.

    Both Levinson and Watson agree that the next big thing on biotech's hot plate is the study of human variation. This means trying to understand, for instance, why one person out of 100 might react differently to a drug than others.

    The catch phrase that highlights this area is "personalized medicine," which involves finding ways to make sure a person is prescribed a medication that works just right for him or her.

    Herceptin is an example of personalized medicine since it's a drug that targets patients with breast cancer containing a specific gene.

    Although the company now faces stiff competition, Levinson still is confident about Genentech's current status and its future.

    "Right now I'm more excited than I've ever been because we really established both the business and scientific model here," he said.

    In the next four years, the company has a goal of trying to bring at least 20 new molecules into clinical development, and at least 15 new products or uses for existing ones into the market.

    "I really think we are going to see more important drugs in terms of a molecular basis in the next five to 10 years," Levinson said. "For us, now it's just a matter of continuing to turn the crank and really step it up."

    Genentech just hired its 10,000th employee Monday, and currently has about 8,300 working at its headquarters.

    Mark Jackson, who believes he was employee number 72 when hired as a research assistant in 1980, remembers when Genentech was just a small company started in the corner of a warehouse. (It now occupies 43 buildings in South San Francisco alone.)

    When Genentech went public that year, the verdict was still out as to what both Genentech and biotechnology would become.

    "It seems like a natural progression on one hand because I've pretty much grown up my entire adult life with Genentech. But if I sat down and really thought about it, it really is an amazing thing as to what's happened," said Jackson, who now works in the company's legal department. "We certainly take a lot of pride knowing that the industry looks at Genentech as the birth place of biotechnology."

    www.insidebayarea.com/ci_3679055?sour...
  3. [verwijderd] 6 april 2006 17:19


    DJ US Drug Stocks Lower, Dragged Down By Merck Verdict

    04/06/2006
    Dow Jones News Services
    (Copyright © 2006 Dow Jones & Company, Inc.)


    By Val Brickates Kennedy

    Merck is leading drug stocks lower early Thursday, as shares of the drug maker slid on news that a New Jersey jury had found the drug maker liable in the heart attack of a former Vioxx user.


    The Amex Pharmaceutical Index dipped 0.9% to 327.01 and the Amex Biotechnology Index slipped 1.3% to 695.61.


    Merck (MRK) stock fell 4.4% to $34.41. Late Wednesday, a jury found that Merck was liable in contributing to the injury of a former Vioxx user, awarding the man $4.5 million in compensatory damages. The jury is now considering whether it should also award punitive damages.


    The same jury, however, also found that Merck was not liable in the cardiac injuries suffered by a second plaintiff. The two cases had been consolidated before one jury.


    On the biotech side, Novavax (NVAX) declined 10.5% to $5.98. Analysts at RBC Capital Markets cut their rating of the stock to underperform.


    Aastrom Biosciences (ASTM) shares slid 5.6% to $1.68. The stem-cell research group said it had executed a definitive purchase agreement for the sale of about 15.9 million shares to a group of institutional investors for $1.60 a share. Aastrom said it expects to raise approximately $25.5 million from the transaction.

    -Val Brickates Kennedy; 415-439-6400; AskNewswires@dowjones.com

  4. forum rang 10 voda 6 april 2006 20:39
    Ook geen verkeerd product?

    Libido verhogende neusspray

    Wetenschappers doen onderzoek naar libido verhogende neusspray voor vrouwen.

    Het onderzoek gebeurt in het FC Donderscentrum in Nijmegen , in opdracht van een Zwitsers bedrijf dat de spray op de markt brengt. De spray bevat het hormoon testosteron, aldus de woordvoerder van het Nijmeegse centrum voor hersenonderzoek donderdag.

    De spray wordt uitgetest op vrijwilligsters. Na het toedienen wordt met een hersenscan gekeken in hoeverre de spray de opwinding beïnvloedt. ,,We kijken in eerste instantie niet naar de seksuele opwinding, maar naar het algehele opwindingsniveau,’’ aldus de woordvoerder van het FC Donderscentrum, dat is gespecialiseerd in hersenonderzoek.

    Volgens de Zwitserse procudent is het middel speciaal bedoeld ter verhoging van het libido bij vrouwen. Naar een dergelijk middel is veel vraag, stelt het onderzoekscentrum in Nijmegen. Het onderzoek zal zeker enkele maanden duren. De wetenschappers in Nijmegen zijn nog op zoek naar vrijwilligsters.

  5. [verwijderd] 6 april 2006 21:42
    quote:

    voda schreef:

    Ook geen verkeerd product?

    Dat zou oa voor jonge vrouwen in de overgang na bv operatie of chemotherapie bij behandeling van kanker geweldig kunnen zijn!(Er zijn overigens ook testosteron-pleisters en zalfjes op de markt.)Het geven van testosteron kan soms ook zinvol zijn bij osteoporose.

    Door chemotherapie komen veel premenopauzale vrouwen in de overgang. Meestal is dit tijdelijk. Drie tot zes maanden na de laatste behandeling herstellen de eierstokken zich, en komen de menstruaties terug. Bij sommige vrouwen herstellen de eierstokken zich echter niet. Zij komen permanent in de overgang. De kans hierop neemt met de leeftijd toe. Als je jonger bent dan 30 jaar kan je er vrijwel zeker van zijn dat je eierstokken zich herstellen. Boven de 30 jaar neemt de kans dat je blijvend in de overgang komt langzaam toe tot 30 à 40%.
    www.kwfkankerbestrijding.nl/content/p...
    www.kwfkankerbestrijding.nl/content/d...
  7. [verwijderd] 6 april 2006 22:51
    Nog meer testosteron:

    Testosterone Might Help Men With MS
    40 minutes ago

    THURSDAY, April 6 (HealthDay News) -- Testosterone therapy may help improve cognitive function and slow brain atrophy in men with multiple sclerosis (MS), say researchers at the University of California, Los Angeles.

    news.yahoo.com/s/hsn/20060406/hl_hsn
    /testosteronemighthelpmenwithms;_ylt=AvZWE4g1U0ZTqnm7h1KHyXms0NUE;_ylu=X3oDMTA3czJjNGZoBHNlYwM3NTE-
  9. forum rang 10 voda 6 april 2006 23:16
    quote:

    BRUNO0802 schreef:

    Voda je gelooft het niet.Maar na al die dalingen van Crucell is mijn Libido flink gestegen.Schijnbaar heb ik het niet nodig die speciale spray.Als het aandeel maar spanning geeft.
    Nee, een 58-jarige man (van de Molukken) heeft inderdaad geen spray nodig die voor vrouwen ontwikkeld is.

    Een vos verliest wel zijn haren, maar niet zijn streken. (trouwens wel handig bij die monniken).

    Voda
  11. [verwijderd] 7 april 2006 09:12
    hoe snel of hoe langzaam gaat zo'n beursverlating..that's the question..

    06-04-2006 12:36

    Robeco bezorgd over uittocht op de beurs


    AMSTERDAM (ANP-AFX) - Vermogensbeheerder Robeco is niet gelukkig met de reeks bedrijven die de beurs verlaat. "Wij hebben belang bij een grote publieke markt. Elk bedrijf dat verdwijnt, betekent weer een beursfonds minder", zei Robeco-topman George Möller donderdag.
    De bestuursvoorzitter deed zijn uitspraken anderhalve week nadat de Vereniging van Effectenbezitters waarschuwde voor een leegloop op de beurs in Amsterdam.
    "Ik kan me wel vinden in die hartekreet. Robeco is er in principe ook voor dat bedrijven op de beurs blijven", zei Mller. Hij was tot enkele jaren terug als topbestuurder verantwoordelijk voor de effectenbeurs in Amsterdam.
    Oneigenlijk middel
    Robeco heeft als vermogensbeheerder een lange horizon en is daarom niet blij met investeerders die bedrijven van de beurs halen om snel extra waarde te genereren. Het beleggingsbedrijf noemt dat zelfs een "oneigenlijk middel". Mller: "Het argument is dan dat je de bestuurders van een onderneming een extra prikkel moet geven. Dat gebeurt door bedrijven van de beurs te halen en de bestuurders aandelen te geven. Maar het bestuur van een beursgenoteerd bedrijf wordt volgens ons gewoon betaald om maximale waarde te creëren. Het moet in staat zijn de maximale waarde eruit te halen op een openbare markt."
    Vermogensbeheerder Robeco heeft geen trek om de participatiemaatschappijen te volgen en zelf direct geld te steken in ondernemingen. "Wij zijn toch vooral een vermogensbeheerder en zijn goed in beleggen, terwijl participatiemaatschappijen bovenop een onderneming zitten", aldus Möller.
  13. [verwijderd] 7 april 2006 10:13
    Pfizer to acquire neuroscience company Rinat
    Thursday 6 April 2006, 7:12pm EST


    NEW YORK, April 6 (Reuters) - Pfizer Inc (PFE.N: Quote, Profile, Research) said on Thursday it has entered into an agreement to acquire Rinat Neuroscience Corp., a privately held biotechnology company that is developing therapeutic proteins for the treatment of diseases and disorders of the central nervous system.

    The financial terms of the transaction were not disclosed.

    Pfizer said the acquisition was expected to close by the middle of 2006.
    today.reuters.com/business/newsarticl...


  14. [verwijderd] 7 april 2006 23:56
    Altana proves a bitter pill for Goldman in search for buyer

    By Katherine Griffiths (Filed: 07/04/2006)

    Goldman Sachs is struggling to find a buyer for the German drugs company Altana, marking the investment bank's second flop in the pharmaceuticals sector after it also failed to sell the Swiss company Serono.

    There is speculation that Goldman may now try to organise a marriage between Altana and Merck, which lost out to its larger rival Bayer in a battle for Schering last month. Goldman advised Merck on its offer for Schering.

    Analysts believe there will be a wave of deals in the German drugs sector as companies seek to take advantage of substantial cost-cutting and the German government's attempt to stimulate the country's ailing research and development capability.

    Goldman would not comment on the progress of its search to find a buyer for Altana, which is worth more than €5bn (£3.5bn), has 8,800 staff and is based in Konstanz.
    www.telegraph.co.uk/money/main.jhtml?...
  16. [verwijderd] 9 april 2006 20:46
    Affitech Renews Exclusive Worldwide Phage Display License From DKFZ

    The human antibody company, Affitech AS, announced today at BIO 2006 that they have renewed an exclusive worldwide licensing agreement with DKFZ (German Cancer Research Center) of Heidelberg, Germany for the antibody library display patents, otherwise known as "Breitling" IP family. These patents cover the use of full-length pIII phage protein as a scaffold in a phagemid vector, and are one of the fundamental patents for the phagemid display of antibody, antibody fragments and proteins. As the antibody therapeutic market continues to grow with a record number of candidates moving through pre-clinical and clinical trials, Affitech anticipates that all serious entrants in the antibody field will consider the use of these patents. This is backed by the fact that over the past couple of years, Affitech has successfully negotiated cross-licensing agreements involving Breitling IP with leading antibody companies such as Dyax and Xoma.

    The renewed terms provide Affitech the worldwide exclusive license until the expiry of the patents in the respective territories, and include the capability of Affitech to sublicense the IP to any company or organization worldwide. No other terms of the agreement were disclosed.

    Regarding the renewal of the Breitling IP licensing, Dr. Martin Welschof, Chief Executive Officer of Affitech commented: "We are delighted to have renewed this exclusive license and the accompanying sublicensing rights with DKFZ with whom we have had a long-standing relationship going back to the original development of phagemid-based antibody display system. The Breitling family occupies a key position in the antibody field. The IP applies not only to screening libraries, but extends to antibodies discovered and developed for use as diagnostics or therapeutics. With the announcement of this renewal, we expect further sublicensing agreements to follow those already signed with Dyax and Xoma."

    The DKFZ agreement represents another milestone as Affitech continues to progress towards becoming a product-focused human antibody therapeutics company. Several of its in-house discovered antibodies generated by its pioneering CBAS(TM) (Cell Based Antibody Selection) technology are currently undergoing pre-clinical development.
    www.redorbit.com/news/health/
    463553/affitech_renews_exclusive_worldwide_phage_display_license_from_dkfz_breitling/index.html?source=r_health
  17. [verwijderd] 10 april 2006 12:51

    =DJ INTERVIEW: Serono Actively Looks At Acquisition Targets


    By Stefanie Weitz

    Of DOW JONES NEWSWIRES


    ZURICH (Dow Jones)--Biotechnology company Serono SA (SRA) is eyeing one big acquisition or several small ones to actively grow its top line in the near future, Chief Financial Officer Stuart Grant told Dow Jones Newswires in an interview Monday.


    (MORE TO FOLLOW) Dow Jones Newswires

    04-10-06 0324ET

  18. [verwijderd] 10 april 2006 13:01
    quote:

    Dirk R. Wijnen schreef:

    =DJ INTERVIEW: Serono Actively Looks At Acquisition Targets

    By Stefanie Weitz
    Of DOW JONES NEWSWIRES

    ZURICH (Dow Jones)--Biotechnology company Serono SA (SRA) is eyeing one big acquisition or several small ones to actively grow its top line in the near future, Chief Financial Officer Stuart Grant told Dow Jones Newswires in an interview Monday.

    (MORE TO FOLLOW) Dow Jones Newswires
    04-10-06 0324ET
    Hoi Dirk,
    GS is er maar druk mee, zie ook:
    March 31, 2006 08:10 AM ET
    Serono to raise capital for possible acquistions

    Serono surprised investors on Friday with plans to raise about SFr7.3bn ($5.6 billion) for potential acquisitions through issuing new shares after failing to attract a buyer for the Swiss biotechnology company.

    Shares, which fell as much as 9 per cent, were 6 per cent lower by mid-morning at SFr909.5.

    Serono hired Goldman Sachs last November to find "strategic options" for the Bertarelli family's controlling 62 per cent stake. A number of large pharmaceutical groups - including GlaxoSmithKline, Novartis and Pfizer had been tipped as buyers. However, the company's attractiveness has been in doubt as its top-selling multiple sclerosis drug Rebif faces the prospect of growing competition, coupled with Serono's weak pipeline of new drugs to replace possible lost sales.

    On Friday, Serono said it would seek shareholder approval to provide it with the financial capacity to pursue possibilities that include an acquisition. "The strategic review announced in November 2005 is on-going and could result in a sale of, merger of, or one or more acquisitions by, the company," it said in a statement.

    The company plans to issue up to 7.6m new bearer shares that are worth about SFr 7.3bn based on Serono's closing share price on Thursday.

    The capital increase would be worth around 7.3 billion Swiss francs ($5.6bn), based on Thursday's closing price. Serono, which has a market capitalisation of $10.4bn, said that the capital increase could be executed all at once or in instalments.
    news.moneycentral.msn.com/provider/pr...
    www.iex.nl/forum/topic.asp?forum=228&...
    *********
    Goldman Sachs is struggling to find a buyer for the German drugs company Altana, marking the investment bank's second flop in the pharmaceuticals sector after it also failed to sell the Swiss company Serono.

    There is speculation that Goldman may now try to organise a marriage between Altana and Merck, which lost out to its larger rival Bayer in a battle for Schering last month. Goldman advised Merck on its offer for Schering.
    www.telegraph.co.uk/money/main.jhtml?...
  20. [verwijderd] 10 april 2006 23:13
    Serono Abandons Search for Buyer, Seeks Acquisitions (Update8)

    ``We're not adverse to a single large acquisition, neither are we adverse to multiple smaller transactions,'' he said.

    One candidate may be UCB SA, the Belgian maker of the allergy drug Zyrtec, according to Bank Sarasin in Zurich. Others may include Altana AG and Merck KGaA of Germany, whose bid for rival Schering AG was trumped by BASF AG last month, said Daniel Wendorff, an analyst at WestLB Equity Markets in Dusseldorf.

    Merck spokesman Steffen Mueller and Altana's Thomas Gauly declined to comment.

    Grant declined to comment on any talks with companies or on the price the Bertarellis are seeking for their controlling stake. Serono hasn't set a deadline for making an acquisition, Grant said. The share capital that the company plans to issue will be valid for two years, he said.

    Rebif Rivals

    The company has been buying products to reduce dependence on the multiple-sclerosis medicine Rebif and the fertility drug Gonal-f, which together generates three-quarters of the company's sales. Rebif was first sold in 1998 and may face competition from new oral treatments as well as Tysabri, which Biogen Idec Inc. and Elan Corp. may return to the market in coming months.

    The product acquisitions have allowed Serono to move into new disease areas such as oncology and dermatology.

    Serono acquired rights to Genentech Inc. and Xoma Ltd.'s psoriasis therapy Raptiva outside the U.S. and Asia and experimental cancer drugs from companies including Genmab A/S and Rigel Pharmaceuticals Inc.

    ``We have been more focused on acquiring products in the past and this has helped us strengthen our research and development,'' Grant said. ``But now we need to focus on growing the top line in the short- to medium-term and to do that we'll need to migrate into another strategy.''
    www.bloomberg.com/apps/news?pid=10000...
1.189 Posts
Pagina: «« 1 ... 5 6 7 8 9 ... 60 »» | Laatste |Omhoog ↑

Direct naar Forum

Indices

AEX 913,56 +0,02%
EUR/USD 1,0867 -0,16%
FTSE 100 8.438,65 -0,08%
Germany40^ 18.689,80 -0,26%
Gold spot 2.378,23 -0,35%
NY-Nasdaq Composite 16.698,32 -0,26%

Stijgers

Vastned
+2,88%
INPOST
+2,77%
RENEWI
+1,99%
Aperam
+1,96%
JDE PE...
+1,95%

Dalers

SIGNIF...
-5,53%
Avantium
-5,52%
EBUSCO...
-3,28%
IMCD
-3,22%
NX FIL...
-2,37%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!